Ni Fan1, Ke Xu2, Yuping Ning1, Robert Rosenheck2, Daping Wang1, Xiaoyin Ke1, Yi Ding1, Bin Sun1, Chao Zhou1, Xuefeng Deng3, Waikwong Tang4, Hongbo He5. 1. Guangzhou Brain Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. 2. Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT 06510, USA. 3. Guangzhou Baiyun Mental Hospital, 586 North of Baiyun Road, Baiyun District, Guangzhou, Guangdong 510440, China. 4. Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong. 5. Guangzhou Brain Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. Electronic address: hongbo_he@yeah.net.
Abstract
OBJECTIVE: Although concern about chronic ketamine abuse has grown, the characteristic symptomatology of chronic ketamine users has yet to be examined. This study aims to measure the psychotic, depressive and anxiety symptoms in chronic ketamine users. METHODS: A group of chronic ketamine users in Guangzhou, China were evaluated. The socio-demographic and drug use characteristics of subjects were documented. Symptoms of psychosis, depression, anxiety were evaluated by the Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). The severity of the symptoms was identified by standard severity cutoffs. RESULTS: The PANSS total score, positive symptom, negative symptom, general psychopathology subscale score were 45.3±8.4, 8.0±1.7, 13.2± 3.9 and 24.2± 4.9 respectively. BDI and BAI score was 13.1±6.5 and 15.7±9.6 respectively. 77.5% and 46.0% of the subjects showed moderate to severe depressive symptoms and anxiety symptoms respectively. The BDI score was positively correlated with ketamine use frequency. The BAI score was positively correlated with ketamine use frequency. CONCLUSIONS: Depressive symptoms were commonly presented in chronic ketamine users. The higher ketamine use frequency and dosage were associated with more severe depressive symptoms.
OBJECTIVE: Although concern about chronic ketamine abuse has grown, the characteristic symptomatology of chronic ketamine users has yet to be examined. This study aims to measure the psychotic, depressive and anxiety symptoms in chronic ketamine users. METHODS: A group of chronic ketamine users in Guangzhou, China were evaluated. The socio-demographic and drug use characteristics of subjects were documented. Symptoms of psychosis, depression, anxiety were evaluated by the Positive and Negative Syndrome Scale (PANSS), Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). The severity of the symptoms was identified by standard severity cutoffs. RESULTS: The PANSS total score, positive symptom, negative symptom, general psychopathology subscale score were 45.3±8.4, 8.0±1.7, 13.2± 3.9 and 24.2± 4.9 respectively. BDI and BAI score was 13.1±6.5 and 15.7±9.6 respectively. 77.5% and 46.0% of the subjects showed moderate to severe depressive symptoms and anxiety symptoms respectively. The BDI score was positively correlated with ketamine use frequency. The BAI score was positively correlated with ketamine use frequency. CONCLUSIONS:Depressive symptoms were commonly presented in chronic ketamine users. The higher ketamine use frequency and dosage were associated with more severe depressive symptoms.
Authors: Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R Engel Journal: Schizophr Res Date: 2005-06-27 Impact factor: 4.939
Authors: J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney Journal: Arch Gen Psychiatry Date: 1994-03
Authors: James M Stone; Fiona Pepper; Johnson Fam; Hannah Furby; Emer Hughes; Celia Morgan; Oliver D Howes Journal: Psychopharmacology (Berl) Date: 2013-11-22 Impact factor: 4.530
Authors: Chadi G Abdallah; Lynnette A Averill; Katherine A Collins; Paul Geha; Jaclyn Schwartz; Christopher Averill; Kaitlin E DeWilde; Edmund Wong; Alan Anticevic; Cheuk Y Tang; Dan V Iosifescu; Dennis S Charney; James W Murrough Journal: Neuropsychopharmacology Date: 2016-09-08 Impact factor: 7.853